Moleculin Positive FDA Guidance to Speed Registration Trial in Acute Myeloid Leukemia

 Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025

https://www.prnewswire.com/news-releases/moleculin-receives-positive-fda-guidance-for-acceleration-of-its-registration-enabling-miracle-trial-for-rr-acute-myeloid-leukemia-aml-302375907.html